We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Interpace Biosciences Inc (IDXG) NPV

Sell:$1.47 Buy:$1.47 Change: $0.0175 (1.21%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$1.47
Buy:$1.47
Change: $0.0175 (1.21%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$1.47
Buy:$1.47
Change: $0.0175 (1.21%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.

Contact details

Address:
Waterview Plaza
Suite 310, 2001 Route 46
PARSIPPANY
07054
United States
Telephone:
+1 (412) 2246100
Website:
https://www.interpace.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IDXG
ISIN:
US46062X3035
Market cap:
$6.35 million
Shares in issue:
4.38 million
Sector:
Health Care Services
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Burnell
    President, Chief Executive Officer, Director
  • Christopher Mccarthy
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.